ArticlePDF AvailableLiterature Review

Prevalence of headache in Europe: A review for the Eurolight project

Authors:
  • NTNU-Norwegian University of Science and Technology
  • Public Research Centre for Health Luxembourg, University Basle

Abstract and Figures

The main aim of the present study was to do an update on studies on headache epidemiology as a preparation for the multinational European study on the prevalence and burden of headache and investigate the impact of different methodological issues on the results. The study was based on a previous study, and a systematic literature search was performed to identify the newest studies. More than 50% of adults indicate that they suffer from headache in general during the last year or less, but when asked specifically about tension-type headache, the prevalence was 60%. Migraine occurs in 15%, chronic headache in about 4% and possible medication overuse headache in 1-2%. Cluster headache has a lifetime prevalence of 0.2-0.3%. Most headaches are more prevalent in women, and somewhat less prevalent in children and youth. Some studies indicate that the headache prevalence is increasing during the last decades in Europe. As to methodological issues, lifetime prevalences are in general higher than 1-year prevalences, but the exact time frame of headache (1 year, 6 or 3 months, or no time frame stated) seems to be of less importance. Studies using personal interviews seem to give somewhat higher prevalences than those using questionnaires.
Content may be subject to copyright.
REVIEW ARTICLE
Prevalence of headache in Europe: a review for the Eurolight
project
Lars Jacob Stovner Colette Andree
Received: 19 January 2010 / Accepted: 15 April 2010 / Published online: 16 May 2010
The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract The main aim of the present study was to do an
update on studies on headache epidemiology as a prepara-
tion for the multinational European study on the prevalence
and burden of headache and investigate the impact of dif-
ferent methodological issues on the results. The study was
based on a previous study, and a systematic literature search
was performed to identify the newest studies. More than
50% of adults indicate that they suffer from headache in
general during the last year or less, but when asked specif-
ically about tension-type headache, the prevalence was 60%.
Migraine occurs in 15%, chronic headache in about 4% and
possible medication overuse headache in 1–2%. Cluster
headache has a lifetime prevalence of 0.2–0.3%. Most
headaches are more prevalent in women, and somewhat less
prevalent in children and youth. Some studies indicate that
the headache prevalence is increasing during the last dec-
ades in Europe. As to methodological issues, lifetime
prevalences are in general higher than 1-year prevalences,
but the exact time frame of headache (1 year, 6 or 3 months,
or no time frame stated) seems to be of less importance.
Studies using personal interviews seem to give somewhat
higher prevalences than those using questionnaires.
Keywords Epidemiology Prevalence Headache
Migraine Medication overuse
Introduction
The Eurolight project (http://www.eurolight-online.eu)isan
initiative supported by the EC Public Health Executive
Agency launched in May 2007. Its objectives are to bring
together the relevant medical, scientific and lay organi-
zations, and to gather updated reliable comparable infor-
mation regarding migraine, tension-type and chronic
headache. It will be the first data collection on headaches at
EU level focusing on a holistic, patient-driven and scien-
tifically validated approach, aiming to fill in the main holes
in our knowledge by performing comparable studies on
headache prevalence and impact in selected European
countries (Austria, France, Germany, Italy, Lithuania, the
Netherlands, Spain, UK, Ireland and Luxembourg). A pilot
study has already been performed in Luxembourg. The
present review of the prevalence of various headaches in
Europe was performed as a part of the Eurolight project to
assess the current state of knowledge before the data from
the current project are published.
A previous study on the headache prevalence in Europe
covered the data up till 2005 [1]. The present review will
include all previous studies, including relatively recently
published reviews [13] with the addition of new relevant
studies that have appeared in the years between 2005 and
2009. The way the research methodology can influence the
results has been thoroughly discussed in some of these and
On behalf of the Eurolight Steering Committee.
L. J. Stovner (&)
Department of Neuroscience, Norwegian National Headache
Centre, Norwegian University of Science and Technology,
7006 Trondheim, Norway
e-mail: lars.stovner@ntnu.no
L. J. Stovner
St. Olavs Hospital, 7006 Trondheim, Norway
C. Andree
CRP Sante
´, Luxembourg City, Luxembourg
C. Andree
Department of Pharmaceutical Sciences,
University of Basel, Basel, Switzerland
123
J Headache Pain (2010) 11:289–299
DOI 10.1007/s10194-010-0217-0
other publications [1,4,5]. The aim of the present article
was to give an update on the prevalence of the most
important headache types in Europe, to identify gaps in our
present knowledge and to analyse some methodological
issues in order to choose an optimal methodology for the
studies to be performed for the EUROLIGHT project.
Methodology
Literature search
A comprehensive literature search was performed to iden-
tify population-based studies of headache and migraine.
Searches were performed with PubMed using the expres-
sions ‘‘migraine epidemiology’’, ‘‘headache epidemiology’
and ‘‘migraine prevalence’’ or ‘‘headache prevalence’’ for
each European country. References in relevant publications
have also been examined. Only studies in English, German,
French or Spanish were considered.
Data extraction
The information extracted was the country of origin, year
of publication, population characteristics and the preva-
lence estimates for headache, migraine, tension-type
headache (TTH) and chronic headache, both overall and for
each gender, and for various age categories.
Case definitions
Only studies where the headache diagnoses are made
according to the International Classification of Headache
Disorders, first edition (ICHD-1) from 1988 [6]or
according to ICHD-2 from 2004 [7] have been used. This
classification has later been incorporated in the Interna-
tional Classification of Diseases (ICD-10) [8]. Hence, we
have included epidemiologic studies that have appeared
after 1988 on migraine (ICD-10 diagnosis G43) and TTH
(G44.2), the two types that affect the great majority of
headache patients. For migraine, we have not distinguished
between migraine with (G43.1) and without (G43.0) aura.
This differentiation can reliably be made only in studies
using personal interview, preferably by a headache spe-
cialist. In addition, it is not known whether the two types
differ markedly with regard to the patients’ suffering and
subsequent economic consequences. For practical reasons,
the diagnosis in most headache epidemiologic studies has
been made according to somewhat modified criteria, and
such studies have also been included.
In order to comprise all headache patients, we have also
included epidemiologic studies that have investigated
headache in general. The term ‘‘headache’ is not, however,
defined in the ICHD classifications, and we have therefore
included studies on headache prevalence that appeared
before 1988. For TTH, the term ‘‘chronic’’ has been
applied to patients who have this type of headache for
C15 days per month on average for C3 months (ICHD-1
and -2). In many headache studies, a similar definition has
been given to patients with headache, irrespective of
whether it is of the tension type or not. We have also
gathered data on ‘‘chronic headache’’ (i.e. C15 days per
month or ‘‘daily’’ headache) to assess the prevalence of
these patients who are probably most incapacitated by their
condition. A subgroup of these patients are overusing acute
medication, a condition termed ‘‘Medication overuse
headache’’ (MOH) in the IDHD-2. We have also collected
data on this frequent and possibly preventable condition.
Source populations
For our purpose, we have included only studies performed
on the whole population or a representative sample of the
whole population within a certain age range in a commu-
nity, town or country. We have accordingly not included
studies based on selected populations (clinic based, in
workplaces, among university students, etc.). Since the
primary school is obligatory in all European countries,
studies on headache in children and youth based on schools
have been included.
Period prevalences
For many patients, headache is troublesome only in certain
phases of life. For this reason, most headache epidemio-
logical studies have asked the subjects on headache within a
limited time span, usually the last year. The 1-year preva-
lence figure indicates the proportion of the population that
has an active disease, which is more relevant than lifetime
prevalence for health economic calculations. Data on life-
time prevalence are also considered less reliable due to recall
problems, at least in the elderly. In children and adolescents,
one may assume that the lifetime and 1-year prevalences are
not very different. The studies with 3-month or not specified
timeframe has also been included since these time frames
will also give a fairly accurate estimate of the proportion of
the population with headache in the relatively recent past,
usually not very different from the 1-year prevalence.
Results
Headache
Headache in general has been reported in 49 studies
(Table 1), whereof 34 have concerned headache during
290 J Headache Pain (2010) 11:289–299
123
Table 1 Studies on headache prevalence
Country (year) Reference Time frame Method NAge range (years) Headache Chronic headache
M F Total M F Total
Adults or all ages
Austria (2003) Lampl [37] 1-y P.i. 997 C15 43.6 54.6 49.4
Croatia (2001, 2003) Zivadinov [38,49] L.t. P.i. 3,794 15–65 65.2
Denmark (1991) Rasmussen [10] 1-y P.i. 740 25–64 3
Denmark (1991) Rasmussen [10] L.t. P.i. 740 25–64 93 99 96
Finland (1981) Nikiforow [45] 1-y P.i. 200 [15 69 83 77
Finland (1981) Nikiforow [45] L.t. P.i. 200 [15 91
France (1992) Henry [51] L.t. Q 4,204 5–65 35
France (2002) Henry [20] N.s. Q 10,585 C15 29.2 3.0
France (2003) Lanteri-Minet [17] L.t. Q 10,585 C15 1.6 4.2 3
France (1996) Michel [46] 3-m Q 9,411 [18 39.0 58.0 49
Germany (1994) Gobel [52] L.t. Q 4,061 C18 71.4
Germany (2009) Pfaffenrath [61] 6-m P.i. 7,417 C20 49.5
Germany (2009) Radke [62] 1-y T.i. 7,341 C18 53.0 66.6 60.2
Georgia (2009) Katsarava [12] 1-y P.i. 1,145 C16 46.3 7.6
Greece (1996) Mitsikostas [18] 1-y Q 3,501 15–75 19.0 40.0 29 2.1 6.8 4.5
Italy (1988) D’Alessandro [47] 1-y Q 1,154 [7 35.3 46.2 46
Netherlands (2006) Wiendels [13] 3-m Q 16,232 25–55 3.7
Norway (2000) Hagen [15] 1-y Q 51,383 C20 29.6 45.7 37.7 1.7 2.8 2.4
Norway (2008) Grande [22] 1-y Q 20,598 30–44 2.9
Norway (2008) Russell [43] 1-y Q 21,800 20–80 69.6 84.0 77.2
Portugal (1995) Pereira Monteiro [53] L.t. Q 2,008 All ages 88.6 4.1
Spain (1999) Castillo [14] 1-y Q 2,253 [14 1.0 8.7 4.7
Spain (1994) Laı
´nez [50] L.t. P.i. 2,231 16–65 86.7
Sweden (2001) Dahlof [42] 1-y Q 1,668 18–74 50 76 63
Sweden (2006) Molarius [63] 3-m Q 43,770 18–79 10.4 22.9 16.7
Turkey (2005) Boru [64] L.t P.i. 1,835 15–45 70.9
UK (1975) Waters [65] 1-y Q 1,718 [21 63.5 78.4 71.0
UK (2005) Boardman [48] 1-y Q 1,589 18–90 76
UK (1977) Crisp [66] L.t. Q 727 [7 35.3 46.2
UK (2003) Boardman [67] L.t. Q 1,662 C18 90.2 94.4 92.6
UK (2003) Boardman [67] 3-m Q 1,662 C18 62.0 76.8 70.3
Children and youth
Finland (1983) Sillanpa
¨a
¨[68] 1-y Q 3,784 13 79.8 84.2 82.0
Finland (1994) Metsa
¨honkala [69] 1-y Q 3,580 8–9 36.5
Finland (1991) Sillanpaa [70] 1-y Q 4,405 5 19.5
Finland (1994) Metsa
¨honkala [69] L.t. Q 3,580 8–9 36.5
Germany (2004) Roth-Isigkeit [71] 3-m Q 735 10–18 58.9 73.1 66
Italy (1995) Raieli [72] 1-y P.i. 1,445 11–14 19.9 28.1 23.9
Norway (2004) Zwart [19] 1-y Q 8,255 13–19 69.4 84.2 76.8 0.2 0.8 0.5
Serbia (2007) Milanovic [73] L.t. P.i. 1,259 7–12 32.8
Sweden (2004) Laurell [33] 1-y Q 1,850 7–15 39.3 50.3 44.8
Sweden (1962) Bille [74] L.t. Q 8,993 7–15 58 59.3 58.7
Turkey (2005) Bugdayci [75] N.s. P.i. 5,777 8–16 46.2 52.8 49.2 1.5
Turkey (2007) Akyol L.t. Q 7,721 9–17 79.6 87.1 83.4
Turkey (2006) Karli [76] 1-y Q 2,387 12–17 45.1 59.8 52.2
Turkey (2006) Unalp [77] N.s. Q 2,384 14–18 36 53 46
J Headache Pain (2010) 11:289–299 291
123
the last year or less (here summarized as ‘‘current
headache’’, also including studies where timeframe were
not stated). Calculating the mean of all the studies
comprising more than 205,000 adult participants, current
headache occurred in 53% of adults (61% among women
and 45% among men). The prevalence in the 12 studies
restricted to children and youth, including [37,000 par-
ticipants, was the same (53%), but the only two studies
on the elderly, from Italy, showed a somewhat lower
figure (36%). The total lifetime prevalence of headache
among adults was as expected higher than that of current
headache (77%).
Migraine
The studies on migraine are presented in Table 2. The
mean prevalence of current migraine among [170,000
adults was 14.7% (8% in men and 17.6% in women). In
studies restricted to children and youth ([36,000 partici-
pants), the prevalences were lower (9.2% for all, 5.2% in
boys and 9.1% in girls). Lifetime prevalences were higher
(16, 11 and 20%, respectively).
Most studies only report the prevalence of ‘‘strict
migraine’’, i.e. cases that comply with all the criteria of
either migraine without (ICHD-2 1.1) or with aura
(ICHD-2 1.2). However, if also probable migraine
(ICHD-2 1.6), i.e. cases which fulfil all but one of the
criteria, is included, the proportion with migraine is
almost doubled [9].
TTH
Nineteen studies have reported the TTH prevalences
(Table 3). Overall, the prevalence of current TTH among
[66,000 adults was 62.6%, and chronic TTH (i.e. on
C15 days per month) occurred in 3.3%. Much lower fig-
ures (current TTH 15.9%, chronic TTH 0.9%) were found
in the nine studies among almost 25,000 children and
youth.
Chronic headache and MOH
The definitions of chronic headache varied considerably
among studies. Only two studies used the same criteria for
chronicity as with chronic TTH ([180 days/year [10]or
[14 days/month for more than 3 months during the last
year [11]). Most other studies used a definition of C15 days
per month [1216] or simply daily headache [1719].
The 1-year prevalence of current chronic daily headache
was 4.0% (mean of 8 studies) [10,12,14,15,18,2022]. A
similar figure (4.4%) was found in one study restricted to
the elderly [16], but in studies on children and youth, the
figure was lower (0.5% among 13–19-year-old in Norway),
and 1.5% among 8–16-year-old in Turkey. The highest
figure (7.6%) was found among adults in Georgia [12].
Medication overuse is frequent among those with chronic
headache, and possible medication overuse headache (i.e.
headache C15 days per month and use of medication
C3 months) was found to affect 0.9% in Georgia [12] and
1% of adults in Spain [14,23]. In the HUNT studies in
Norway from the 1990s the prevalence was 1% in adults
[24] and 0.5% in adolescents [25], whereas a more recent
study showed 1.7% [26]. In Germany, a recent study
demonstrated a prevalence of 2% [27].
Cluster headache
In comparison to migraine and TTH, cluster headache is
rare, and to make the diagnosis from questionnaires alone
has never been validated. Therefore, the prevalence should
preferably be made by personal interview and examination
by a neurologist in a large population. A lifetime preva-
lence of 0.326% was found in a study in which the diag-
nosis was made by face-to-face interview by a headache
expert among more than 1,800 inhabitants of a Norwegian
rural community [28]. This is similar to the figure (0.279%)
found in an Italian town among [10,000 patients regis-
tered in the lists of general practitioners, the sample
being representative of the general population [29].
Table 1 continued
Country (year) Reference Time frame Method NAge range (years) Headache Chronic headache
M F Total M F Total
UK (1977) Deubner [78] 1-y Q 600 10–20 74.4 81.5 78.0
UK (1994) Abu-Arefeh [79] 1-y Q 2,165 5–15 66
Elderly
Italy (2001) Prencipe [16] 1-y P.i. 833 C65 36.6 62.1 51 2.5 6 4.4
Italy (2003) Camarda [80] 1-y P.i. 1,031 C65 16.5 26.3 21.8
1-y 1-year prevalence, 3-m 3-month prevalence, 6-m 6-month prevalence, L.t. lifetime prevalence, N.s. prevalence not stated, P.i. personal
interview, T.i. telephone interview, Qquestionnaire, Mmales, Ffemales
292 J Headache Pain (2010) 11:289–299
123
Table 2 Studies on migraine prevalence
Country (year) Reference Time frame Method NAge range (years) Migraine
M F Total
Adults or all ages
Austria (2003) Lampl [37] 1-y P.i. 997 C15 6.1 13.8 10.2
Croatia (2001) Zivadinov [38] 1-y P.i. 3,794 15–65 13 20.2 16.7
Croatia (2001, 2003) Zivadinov [38,49] L.t. P.i. 3,794 15–65 14.8 22.9 19
Denmark (1991) Rasmussen [10] 1-y P.i. 740 25–64 6 15 10
Denmark (1991) Rasmussen [10] L.t. P.i. 740 25–64 8 25 16.1
Denmark (1995) Russell [81] L.t. Q 4,061 40 12 24 18
Denmark (2005) Lyngberg [36] 1-y P.i. 207 25–36 5.4 23.5 15.5
Denmark (2006) Russell [44] 1-y Q 28,195 12–41 13.9 24.3 19.1
France (1992) Henry [51] L.t. Q 4,204 5–65 6.1 17.6 12.1
France (2002) Henry [20] N.s. Q 10,585 C15 10 23 17
France (2005) Lante
´ri-Minet [9] N.s. Q 10,532 C18 6.3 15.7 11.2
France (1996) Michel [46] 3-m Q 9,411 [18 8 18 15
Germany (1994) Gobel [52] L.t. Q 4,061 C18 22 32 27.5
Germany (2009) Pfaffenrath [61] 6-m P.i. 7,417 C20 11.4
Germany (2009) Radke [62] 1-y T.i. 7,341 C18 5.3 15.6 10.6
Georgia (2009) Katsarava [12] 1-y P.i. 1,145 C16 15.6
Hungary (2000) Bank [40] 1-y Q 813 15–80 2.7 6.9 9.6
Netherlands (1999) Launer [41] 1-y Q 6,491 20–65 7.5 25 16.3
Netherlands (1999) Launer [41] L.t. Q 6,491 20–65 13.3 33 23.2
Norway (2000) Hagen [15] 1-y Q 51,383 C20 7.5 15.6 11.6
Norway (2006) Sjaastad [82] N.s. P.i. 1,838 18–65 17.5 28.4 23.0
Norway (2008) Russell [43] L.t. Q 21,800 20–80 18.1 34.1
Portugal (1995) Pereira Monteiro [53] L.t. Q 2,008 All 8.8
Spain (1994) Laı
´nez [50] L.t. P.i. 2,231 16–65 8 17 12
Sweden (2000) Mattsson [83] L.t. Q 722 40–74 31
Sweden (2000) Mattsson [83] 1-y Q 728 40–74 18
Sweden (2001) Dahlo
¨f[42] 1-y Q 1,668 18–74 9.5 16.7 13.2
Sweden (2006) Molarius [63] 3-m Q 43,770 18–79 2.4 5.5 4.0
Switzerland (1994) Merikangas [39] 1-y P.i. 379 29–30 24.6
Turkey (2005) Boru [64] L.t. P.i. 1,835 15–45 15.8
Turkey (2005) Celik [55] L.t. P.i. 386 [14 9.3 29.3 19.9
Turkey (2002) Kececi [56] L.t. P.i. 947 C7 7.9 17.1 12.5
UK (2003) Steiner [57] 1-y T.i. 4,007 16–65 7.6 18.3 14.3
Children and youth
Finland (1994) Metsa
¨honkala [69] L.t. Q 3,580 8–9 3 2.3 2.7
Germany (2007) Fendrich [84] 3-m Q 3,324 12–15 4.4 9.3 6.9
Germany (2009) Heinrich [85] 6-m Q 2,553 9–14 13.1
Greece (1999) Mavromichalis [86] 1-y Q 3,509 4–15 5.2 7.3 6.2
Italy (1995) Raieli [72] 1-y P.i. 1,445 11–14 2.7 3.3 3.0
Norway (2004) Zwart [19] 1-y Q 8,255 13–19 4.8 9.1 7.0
Serbia (2007) Milanovic [73] L.t. P.i. 1,259 7–12 2.1 4.6 3.3
Sweden (2004) Laurell [33] 1-y Q 1,850 7–15 9.8 12.2 11.0
Turkey (2005) Bugdayci [75] N.s. P.i. 5,777 8–16 10.4
Turkey (2004) Zencir [87] N.s. Q 2,490 11–18 6.7 11.0 8.8
Turkey (2006) Karli [76] 1-y Q 2,387 12–17 14.5
Turkey (2007) Akyol [88] L.t. Q 7,721 9–17 7.8 11.7 9.7
J Headache Pain (2010) 11:289–299 293
123
Questionnaires or telephone interviews were used to screen
the population, and suspected cases were interviewed by a
headache specialist to confirm the diagnosis. These high
prevalences are also supported by recent data from a
Swedish twin registry study giving a lifetime prevalence of
around 0.2% [30]. In Germany, suspected cluster headache
cases detected by a questionnaire and interviewed by a
neurologist in a population-based study revealed a preva-
lence of 0.12% [31]. In Georgia, one case was found in
door-to-door survey among 1,145 individuals, which cor-
responds to 0.09% [32].
Increase in headache
By studying headache prevalence with an interval of some
years in the same community and using the same method, it
may be possible to study time-trends in headache preva-
lence. A study from Sweden indicates a marked increase of
Table 3 Studies on the prevalence of tension-type headache
Country (year) Reference Time frame Method NAge range
(years)
TTH Chronic TTH
M F Total M F Total
Adults
Croatia (2001, 2003) Zivadinov [49] L.t. P.i. 3,794 15–65 32.3 37.1 34.8
Denmark (1991) Rasmussen [10] 1-y P.i. 740 25–64 63 86 74
Denmark (1991) Rasmussen [10] L.t. P.i. 740 25–64 69 88 78 3.0
Denmark (2005) Lyngberg [36] 1-y P.i. 207 25–36 81.5 90.4 86.5 4.8
Denmark (2006) Russell [44] 1-y Q 28,195 12–41 78.9 92.5 86.0 0.5 1.3 0.9
Georgia (2009) Katsarava [12] 1-y P.i. 1,145 C16 37.3 3.8
Germany (1994) Gobel [52] L.t. Q 4,061 C18 37 39 38 3.0 3.0 3.0
Germany (2009) Pfaffenrath [61] 6-m P.i. 7,417 C20 31.5 1.25
Germany (2009) Radke [62] 1-y T.i. 7,341 C18 53.0 66.6 60.2
Norway (2008) Grande [22] 1-y Q 20,598 30–44 1.6 3.7 2.8
Portugal (2005) Pereira Monteiro [53] L.t. Q 2,008 All ages 48.7 4.1
Turkey (2003) Koseoglu [89] 1-y P.i. 1,146 45–64 18.8 6.3
Children/youth
Finland (2002) Anttila [90] N.s. Q 1,135 12 12.2 0
Germany (2007) Fendrich [84] 3-m Q 3,324 12–15 19.1 21.2 20.2 0.2
Norway (2004) Zwart [19] 1-y Q 8,255 13–19 12.5 23.2 18.0
Serbia (2007) Milanovic [73] L.t. P.i. 1,259 7–12 0.9 1.7 1.3
Sweden (2004) Laurell [33] 1-y Q 1,850 7–15 7.9 11.8 9.8
Turkey (2005) Bugdayci [75] N.s. P.i. 5,777 8–16 24.7 1.5
Turkey (2004) Kaynak Key [91] N.s. Q 2,226 17–21 14.3 22.7 20.35 0.8 2.8 1.9
Turkey (2006) Unalp [77] 1-y Q 2,384 14–18 5.7
For abbreviations see Table 1
Table 2 continued
Country (year) Reference Time frame Method NAge range (years) Migraine
M F Total
Turkey (2006) Unalp [77] 1-y Q 2,384 14–18 9.6
UK (1994) Abu-Arefeh [79] 1-y Q 2,165 5–15 9.7 11.5 10.6
Elderly
Italy (2001) Prencipe [16] 1-y P.i. 833 C65 7.4 13.8 11
Italy (2003) Camarda [80] 1-y P.i. 1,031 C65 2.3 6.4 4.6
For abbreviations see Table 1
294 J Headache Pain (2010) 11:289–299
123
both headache and migraine in schoolchildren over a per-
iod of 40 years [33], and in a Finnish community there was
a significant increase among 8-year-old children in head-
ache (and abdominal pain) over a 10-year period [34]. In
another Finnish study, three population-based studies on
migraine and other headaches among 7-year-old children
conducted in 1974, 1992 and 2002 with almost identical
study design indicated increased incidence rates both of
headaches in general (incidence in the 3 years: 58, 156,
278/1,000 person-years) and migraine (20, 59 and 133)
[35]. Among young adults (25–36 years) in Denmark, there
was over a 12-year period a significant increase in TTH,
particularly the frequent type. There was also a significant
increase in the proportion with relatively frequent
migraine, but the increase for migraine in general was not
significant [36].
Methodological analyses
To explore to which degree the method of data collection
in epidemiologic studies is important for the results, we
compared the mean prevalence of studies in adults using
either personal interview or questionnaire. For 1-year
prevalences (both sexes) of migraine, the mean of the five
studies using personal interview [10,3639] was 15.3%,
compared to 14.0% in the five studies using questionnaires
[15,4044]. For headache in general, the total prevalence
seemed to be higher in the three studies using personal
interview [12,37,45] than in the eight studies using
questionnaires [15,18,20,42,43,4648] (57.6 vs. 40.6%).
For lifetime prevalences of headache in general, the mean
prevalence was somewhat higher in the four studies using
personal interview [10,45,49,50] than in the four using
questionnaires [5154] (84.7 vs. 71.9%). However, for
lifetime prevalences of migraine, the mean of the five
studies using personal interview [10,38,50,55,56] was
somewhat lower than in the four studies using question-
naires [41,5153] (15.9 vs. 17.9%).
As to the effect of using different timeframes in the
studies, there was little difference between the migraine
prevalence in those studies in which the timeframe was not
stated [9,51] compared to the studies asking about head-
ache during the last year [10,15,36,37,4042,49,57]
(12.9 vs. 13.0%).
Discussion
Aggregating studies that have used different methods of
data collection and somewhat variable timeframes for
headache (during the last year or less), the present survey
indicates that more than 50% of the population in Europe
are current headache sufferers, and almost 15% suffer from
migraine. During the last years, more attention has been
drawn to the importance of TTH on the public health, and it
seems that [60% suffer from this headache type. It is a
paradox that the prevalence of TTH is higher than that of
headache in general. Probably, this has to do with the way
studies were performed. More detailed questions in studies
aimed at making specific diagnoses may elicit higher
positive rates than studies using only general questions
about headache. Chronic headache (i.e. on more than
15 days per month) seems to affect around 4% of the adult
population, and MOH 1–2%. For cluster headache, the 1-
year prevalence is not known, but the lifetime prevalence
seems to be around 0.2–0.3%. Other primary headaches are
even rarer, and the prevalence of these has not been esti-
mated in population-based studies. The prevalence of
headache and migraine is higher among women than
among men [1]. In children and youth, the migraine
prevalence is lower than among adults, but the prevalence
of headache in general seems to be as high. Several studies
also indicate a marked increase in headache prevalence
over the decades, particularly in studies on children and
youth, and also in one study on adults.
In this report, we have only considered the main primary
headaches. One reason for this is that reasonably certain
diagnosis of secondary headache requires extensive clinical
and medical investigations, and often follow-up, which is
not feasible in most population-based epidemiologic stud-
ies. An exception to this is medication overuse headache
(MOH) since relatively many studies attempt to estimate
the prevalence of those that might have this condition
(‘‘possible MOH’’), although a certain diagnosis of this
requires both treatment and follow-up. Secondary head-
aches due to serious diseases with a grave prognosis are
quite rare although secondary headaches related to more
trivial causes, like fever or hangover, occur relatively often
[58].
Most of the studies on headache prevalence so far stems
from Western Europe. There are only a few studies from
Eastern Europe (Georgia, Croatia, Serbia and Hungary). In
addition, there are still relatively few studies on TTH. Most
studies this far concern headache in general and migraine.
As to the methodological issues, we have tried to
compare the results from the studies using different
methods of data collection. Only for migraine and head-
ache in general in adults could meaningful comparisons be
made; in TTH or in children or elderly, there were too few
studies available. In general, the figures obtained with
personal interview were somewhat higher than those
obtained with questionnaire. For migraine, the difference
between the two methods was around 10% (15.4 vs 14.0%)
for 1-year prevalence, but almost 30% for lifetime preva-
lence (22.2 vs. 15.9%). For headache in general, the dif-
ference in 1-year prevalence was 30% (57.6 vs 40.6%), but
J Headache Pain (2010) 11:289–299 295
123
for this category, there were only three studies using per-
sonal interview, which will make the estimates less accu-
rate. For lifetime prevalences, the figure based on
questionnaire studies was 15% lower (84.7 vs. 71.9%).
These differences may also reflect variations in the how the
ICHD-2 criteria are applied as most questionnaire studies
use somewhat modified criteria, whereas studies based on
personal interviews tend to use strict criteria. In sum,
personal interview seem to be a somewhat more sensitive
method for obtaining data on headache suffering, and
questionnaires are likely to underestimate prevalences to
some degree.
It has previously been demonstrated that the way the
introductory screening question is asked makes a great
difference in headache prevalence. Quite predictably, a
neutral screening question (e.g. ‘‘have you had headache/
migraine’) will give markedly higher estimates than
questions specifying some degree/severity/frequency of
headache suffering (e.g. ‘‘have you suffered from head-
ache/migraine’’, ‘‘have you had severe headache?’’,
‘have you had repeated episodes of headache?’’, etc.)
[1]. In order to obtain answers from as many headache
sufferers as possible in epidemiologic studies, it is there-
fore probably better to use a neutral screening question,
and then ask additional questions on headache severity,
frequency, duration and impact to define groups of head-
ache sufferers that are of clinical and economical impor-
tance [1].
The ways the ICHD criteria are applied and which
diagnoses are included are also of great importance. It has
been found that the prevalence of migraine almost doubles
if the diagnosis probable migraine (i.e. patients fulfilling all
migraine criteria except one) is included [9,20,51,59].
Among the European studies, the highest migraine preva-
lences has been found in a yet unpublished study from
Luxembourg (29%) performed by one of the authors (CA).
This study has used the ‘‘ID migraine’’ [60] which is a
screening instrument consisting of only three questions.
This instrument has been validated against the ICHD-2
criteria in clinical settings, showing a high sensitivity and
somewhat lower specificity. Probably, this method will
include many patients with probable migraine, and thereby
it will tend to show higher prevalence compared to the
studies using strict ICHD criteria for definite migraine.
The problem of multiple headache types occurring in the
same patient may create large problems in headache epi-
demiologic studies. Generally, it is considered that with
personal interview and examination, many different head-
aches can be diagnosed. With interview performed by
trained personnel, migraine and TTH can be differentiated
in the same person, but with questionnaires, it is usually
wise to let the patient answer the questionnaire based on
the altogether most bothersome headache [4].
Conclusions
The present study indicates that 50% of Europeans have an
active headache disorder. However, there are large varia-
tions, and part of this variation is caused by methodological
differences between studies. Around 15% seem to suffer
from migraine, 4% have chronic headache and possibly 1–
2% medication overuse headache. During their lifetime,
0.2–0.3% has had cluster headache. Headaches are pre-
valent in both sexes and in all age groups, but women
between 20 and 50 years are those who have the highest
prevalences. Data on TTH is still too scarce in Europe, and
data on prevalence of any headache is lacking from most of
Eastern Europe.
As to the method to be used in headache epidemiologic
studies, personal interview will give the most reliable
diagnoses and the highest prevalence estimates, but when
the aim was to diagnose only the most bothersome of the
headaches occurring in one person, questionnaires seem to
perform quite well. A neutral screening question supple-
mented with questions on headache severity and frequency
will probably be the most sensitive method.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Stovner LJ, Zwart JA, Hagen K, Terwindt G, Pascual J (2006)
Epidemiology of headache in Europe. Eur J Neurol 13(4):333–
345
2. Stovner LJ, Hagen K (2006) Prevalence, burden, and cost of
headache disorders. Curr Opin Neurol 19(3):281–285
3. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A
et al (2007) The global burden of headache: a documentation of
headache prevalence and disability worldwide. Cephalalgia
27(3):193–210
4. Stovner LJ, Scher AI (2005) Epidemiology of Headache. In:
Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch
KMA (eds) The Headaches, 3rd edn. Lippincott Williams &
Wilkins, Philadelphia, pp 17–25
5. Stovner LJ (2006) Headache epidemiology: how and why? J
Headache Pain 7(3):141–144
6. Headache Classification Committee of the International Head-
ache Society (1988) Classification and diagnostic criteria for
headache disorders, cranial neuralgias and facial pain. Cepha-
lalgia 8(Suppl 7):1–96
7. Headache Classification Subcommittee of the International
Headache Society (2004) The international classification of
headache disorders, 2nd edn. Cephalalgia 24(Suppl 1):1–150
8. International Headache Society (1997) ICD-10 guide for head-
aches. Cephalalgia 17(Suppl 19):1–91
9. Lanteri-Minet M, Valade D, Geraud G, Chautard MH, Lucas C
(2005) Migraine and probable migraine–results of FRAMIG 3, a
French nationwide survey carried out according to the 2004 IHS
classification. Cephalalgia 25(12):1146–1158
296 J Headache Pain (2010) 11:289–299
123
10. Rasmussen BK, Jensen R, Schroll M, Olesen J (1991) Epidemi-
ology of headache in a general population—a prevalence study. J
Clin Epidemiol 44(11):1147–1157
11. Grande RBA, Gulbrandsen K, Lundqvist P, Russell C et al (2007)
Prevalence of chronic primary headache in the general popula-
tion. Cephalalgia 27(6):649
12. Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti
M, Janelidze M et al (2009) Primary headache disorders in the
Republic of Georgia: prevalence and risk factors. Neurology
73(21):1796–1803
13. Wiendels NJ, Knuistingh Neven A, Rosendaal FR, Spinhoven P,
Zitman FG, Assendelft WJ et al (2006) Chronic frequent head-
ache in the general population: prevalence and associated factors.
Cephalalgia 26(12):1434–1442
14. Castillo J, Munoz P, Guitera V, Pascual J (1993) Epidemiology of
chronic daily headache in the general population. Headache
39:190–196
15. Hagen K, Zwart JA, Vatten L, Stovner LJ, Bovim G (2000) Prev-
alence of migraine and non-migrainous headache–head-HUNT, a
large population-based study. Cephalalgia 20(10):900–906
16. Prencipe M, Casini AR, Ferretti C, Santini M, Pezzella F, Scal-
daferri N et al (2001) Prevalence of headache in an elderly
population: attack frequency, disability, and use of medication. J
Neurol Neurosurg Psychiatry 70(3):377–381
17. Lanteri-Minet M, Auray JP, El Hasnaoui A, Dartigues JF, Duru
G, Henry P et al (2003) Prevalence and description of chronic
daily headache in the general population in France. Pain 102(1–
2):143–149
18. Mitsikostas DD, Tsaklakidou D, Athanasiadis N, Thomas A
(1996) The prevalence of headache in Greece: correlations to
latitude and climatological factors. Headache 36(3):168–173
19. Zwart JA, Dyb G, Holmen TL, Stovner LJ, Sand T (2004) The
prevalence of migraine and tension-type headaches among ado-
lescents in Norway The Nord-Trondelag Health Study (Head-
HUNT-Youth), a large population-based epidemiological study.
Cephalalgia 24(5):373–379
20. Henry P, Auray JP, Gaudin AF, Dartigues JF, Duru G, Lanteri-
Minet M et al (2002) Prevalence and clinical characteristics of
migraine in France. Neurology 59(2):232–237
21. Wiendels NJ, van Haestregt A, Knuistingh Neven A, Spinhoven
P, Zitman FG, Assendelft WJ et al (2006) Chronic frequent
headache in the general population: comorbidity and quality of
life. Cephalalgia 26(12):1443–1450
22. Grande RB, Aaseth K, Gulbrandsen P, Lundqvist C, Russell MB
(2008) Prevalence of primary chronic headache in a population-
based sample of 30- to 44-year-old persons. The Akershus study
of chronic headache. Neuroepidemiology 30(2):76–83
23. Colas R, Munoz P, Temprano R, Gomez C, Pascual J (2004)
Chronic daily headache with analgesic overuse: epidemiology
and impact on quality of life. Neurology 62(8):1338–1342
24. Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J (2003) Anal-
gesic use: a predictor of chronic pain and medication overuse
headache: the Head-HUNT Study. Neurology 61(2):160–164
25. Dyb G, Holmen TL, Zwart JA (2006) Analgesic overuse among
adolescents with headache: the Head-HUNT-Youth Study. Neu-
rology 66(2):198–201
26. Aaseth K, Grande RB, Kvaerner KJ, Gulbrandsen P, Lundqvist C,
Russell MB (2008) Prevalence of secondary chronic headaches in
a population-based sample of 30–44-year-old persons The
Akershus study of chronic headache. Cephalalgia 28(7):705–713
27. Katsarava Z, Diener HC (2008) Medication overuse headache in
Germany. Cephalalgia 28(11):1221–1222
28. Sjaastad O, Bakketeig LS (2003) Cluster headache prevalence
Vaga study of headache epidemiology. Cephalalgia 23(7):528–533
29. Torelli P, Beghi E, Manzoni GC (2005) Cluster headache preva-
lence in the Italian general population. Neurology 64(3):469–474
30. Ekbom K, Svensson DA, Pedersen NL, Waldenlind E (2006)
Lifetime prevalence and concordance risk of cluster headache in
the Swedish twin population. Neurology 67(5):798–803
31. Katsarava Z, Obermann M, Yoon MS, Dommes P, Kuznetsova J,
Weimar C et al (2007) Prevalence of cluster headache in a
population-based sample in Germany. Cephalalgia 27(9):1014–
1019
32. Katsarava Z, Dzagnidze A, Kukava M, Mirvelashvili E, Djibuti
M, Janelidze M et al (2009) Prevalence of cluster headache in the
Republic of Georgia: results of a population-based study and
methodological considerations. Cephalalgia 29(9):949–952
33. Laurell K, Larsson B, Eeg-Olofsson O (2004) Prevalence of
headache in Swedish schoolchildren, with a focus on tension-type
headache. Cephalalgia 24(5):380–388
34. Santalahti P, Aromaa M, Sourander A, Helenius H, Piha J (2005)
Have there been changes in children’s psychosomatic symptoms?
A 10-year comparison from Finland. Pediatrics 115(4):e434–
e442
35. Anttila P, Metsahonkala L, Sillanpaa M (2006) Long-term trends
in the incidence of headache in Finnish schoolchildren. Pediatrics
117(6):e1197–e1201
36. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R (2005) Has
the prevalence of migraine and tension-type headache changed
over a 12-year period? A Danish population survey. Eur J Epi-
demiol 20(3):243–249
37. Lampl C, Buzath A, Baumhackl U, Klingler D (2003) One-year
prevalence of migraine in Austria: a nation-wide survey. Ceph-
alalgia 23(4):280–286
38. Zivadinov R, Willheim K, Jurjevic A, Sepic-Grahovac D, Bucuk
M, Zorzon M (2001) Prevalence of migraine in Croatia: a pop-
ulation-based survey. Headache 41(8):805–812
39. Merikangas KR, Whitaker AE, Isler H, Angst J (1994) The
Zurich Study: XXIII Epidemiology of headache syndromes in the
Zurich cohort study of young adults. Eur Arch Psychiatry Clin
Neurosci 244(3):145–152
40. Bank J, Marton S (2000) Hungarian migraine epidemiology.
Headache 40:164–169
41. Launer LJ, Terwindt GM, Ferrari MD (1999) The prevalence and
characteristics of migraine in a population-based cohort: the
GEM study. Neurology 53(3):537–542
42. Dahlof C, Linde M (2001) One-year prevalence of migraine in
Sweden: a population-based study in adults. Cephalalgia
21(6):664–671
43. Russell MB, Kristiansen HA, Saltyte-Benth J, Kvaerner KJ
(2008) A cross-sectional population-based survey of migraine
and headache in 21,177 Norwegians: the Akershus sleep apnea
project. J Headache Pain 9(6):339–347
44. Russell MB, Levi N, Saltyte-Benth J, Fenger K (2006) Tension-
type headache in adolescents and adults: a population based study
of 33,764 twins. Eur J Epidemiol 21(2):153–160
45. Nikiforow R (1981) Headache in a random sample of 200 per-
sons: a clinical study of a population in northern Finland.
Cephalalgia 1(2):99–107
46. Michel P, Pariente P, Duru G, Dreyfus JP, Chabriat H, Henry P
et al (1996) MIG ACCESS: a population-based, nationwide,
comparative survey of access to care in migraine in France.
Cephalalgia 16(1):50–55
47. D’Alessandro R, Benassi G, Lenzi PL, Gamberini G, Sacquegna
T, De Carolis P et al (1988) Epidemiology of headache in the
Republic of San Marino. J Neurol Neurosurg Psychiatry
51(1):21–27
48. Boardman HF, Thomas E, Millson DS, Croft PR (2005) One-year
follow-up of headache in an adult general population. Headache
45(4):337–345
49. Zivadinov R, Willheim K, Sepic-Grahovac D, Jurjevic A, Bucuk
M, Brnabic-Razmilic O et al (2003) Migraine and tension-type
J Headache Pain (2010) 11:289–299 297
123
headache in Croatia: a population-based survey of precipitating
factors. Cephalalgia 23(5):336–343
50. Laı
´nez MJA, Vioque J, Herna
´ndez-Aguado I, Titus F (1994)
Prevalence of migraine in Spain. An assessment of the ques-
tionnaire’s validity by clinical interview. Frontiers in headache
research: headache classification and epidemiology. Raven Press,
Ltd., New York, pp 221–225
51. Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R
(1992) A nationwide survey of migraine in France: prevalence
and clinical features in adults. Cephalalgia 12(4):229–237
52. Gobel H, Petersen-Braun M, Soyka D (1994) The epidemiology
of headache in Germany: a nationwide survey of a representative
sample on the basis of the headache classification of the Inter-
national Headache Society. Cephalalgia 14(2):97–106
53. Monteiro JMP (1995) Cefaleias: Estudo Epidemiologico e clinico
da uma populacao urbana, thesis
54. Boardman HF, Thomas E, Croft PR, Millson DS (2003) Epide-
miology of headache in an English district. Cephalalgia
23(2):129–137
55. Celik Y, Ekuklu G, Tokuc B, Utku U (2005) Migraine prevalence
and some related factors in Turkey. Headache 45(1):32–36
56. Kececi H, Dener S (2002) Epidemiological and clinical char-
acteristics of migraine in Sivas, Turkey. Headache 42(4):275–
280
57. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J,
Lipton RB (2003) The prevalence and disability burden of adult
migraine in England and their relationships to age, gender and
ethnicity. Cephalalgia 23(7):519–527
58. Rasmussen BK, Olesen J (1992) Symptomatic and nonsymp-
tomatic headaches in a general population. Neurology 42(6):
1225–1231
59. Gobel H (1994) Paper-pencil tests for retrospective and pro-
spective evaluation of primary headaches on the basis of the IHS
criteria. Headache 34(10):564–568
60. Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J,
Hettiarachchi J et al (2003) A self-administered screener for
migraine in primary care: the ID Migraine validation study.
Neurology 61(3):375–382
61. Pfaffenrath V, Fendrich K, Vennemann M, Meisinger C, Ladwig
KH, Evers S et al (2009) Regional variations in the prevalence of
migraine and tension-type headache applying the new IHS cri-
teria: the German DMKG Headache Study. Cephalalgia
29(1):48–57
62. Radtke A, Lempert T, Gresty MA, Brookes GB, Bronstein AM,
Neuhauser H (2002) Migraine and Meniere’s disease: is there a
link? Neurology 59(11):1700–1704
63. Molarius A, Tegelberg A (2006) Recurrent headache and
migraine as a public health problem—a population-based study in
Sweden. Headache 46(1):73–81
64. Boru UT, Kocer A, Luleci A, Sur H, Tutkan H, Atli H (2005)
Prevalence and characteristics of migraine in women of repro-
ductive age in Istanbul, Turkey: a population based survey. To-
hoku J Exp Med 206(1):51–59
65. Waters WE, O’Connor PJ (1975) Prevalence of migraine. J
Neurol Neurosurg Psychiatry 38(6):613–616
66. Crisp AH, Kalucy RS, McGuinness B, Ralph PC, Harris G (1977)
Some clinical, social and psychological characteristics of
migraine subjects in the general population. Postgrad Med J
53(625):691–697
67. Boardman HF, Thomas E, Millson DS, MacGregor EA, Laughey
WF, Croft PR (2003) North Staffordshire Headache Survey:
development, reliability and validity of a questionnaire for use in
a general population survey. Cephalalgia 23(5):325–331
68. Sillanpa
¨a
¨M (1983) Prevalence of headache in prepuberty.
Headache 23(1):10–14
69. Metsa
¨honkala L, Sillanpa
¨a
¨M (1994) Migraine in children—an
evaluation of the IHS criteria. Cephalalgia 14(4):285–290
70. Sillanpaa M, Piekkala P, Kero P (1991) Prevalence of headache
at preschool age in an unselected child population. Cephalalgia
11(5):239–242
71. Roth-Isigkeit A, Thyen U, Raspe HH, Sto
¨ven H, Schmucker P
(2004) Reports of pain among German children and adolescents:
an epidemiological study. Acta Paediatr 93(2):258–263
72. Raieli V, Raimondo D, Cammalleri R, Camarda R (1995)
Migraine headaches in adolescents: a student population-based
study in Monreale. Cephalalgia 15(1):5–12
73. Milovanovic M, Jarebinski M, Martinovic Z (2007) Prevalence of
primary headaches in children from Belgrade, Serbia. Eur J
Paediatr Neurol 11(3):136–141
74. Bille B (1962) Migraine in school children. A study of the inci-
dence and short-term prognosis, and a clinical, psychological and
electroencephalographic comparison between children with
migraine and matched controls. Acta Paediatr 51:1–151
75. Bugdayci R, Ozge A, Sasmaz T, Kurt AO, Kaleagasi H, Karak-
elle A et al (2005) Prevalence and factors affecting headache in
Turkish schoolchildren. Pediatr Int 47(3):316–322
76. Karli N, Akis N, Zarifoglu M, Akgoz S, Irgil E, Ayvacioglu U
et al (2006) Headache prevalence in adolescents aged 12 to 17: a
student-based epidemiological study in Bursa. Headache
46(4):649–655
77. Unalp A, Dirik E, Kurul S (2006) Prevalence and characteristics
of recurrent headaches in Turkish adolescents. Pediatr Neurol
34(2):110–115
78. Deubner DC (1977) An epidemiologic study of migraine and
headache in 10–20 year olds. Headache 17(4):173–180
79. Abu-Arefeh I, Russell G (1994) Prevalence of headache and
migraine in schoolchildren. BMJ 309(6957):765–769
80. Camarda R, Monastero R (2003) Prevalence of primary head-
aches in Italian elderly: preliminary data from the Zabut Aging
Project. Neurol Sci 24(Suppl 2):S122–S124
81. Russell MB, Rasmussen BK, Thorvaldsen P, Olesen J (1995)
Prevalence and sex-ratio of the subtypes of migraine. Int J Epi-
demiol 15(1):612–618
82. Sjaastad O, Bakketeig LS (2008) Migraine without aura: com-
parison with cervicogenic headache. Vaga study of headache
epidemiology. Acta neurol Scand 117(6):377–383
83. Mattsson P, Svardsudd K, Lundberg PO, Westerberg CE (2000)
The prevalence of migraine in women aged 40–74 years: a
population-based study. Cephalalgia 20(10):893–899
84. Fendrich K, Vennemann M, Pfaffenrath V, Evers S, May A,
Berger K et al (2007) Headache prevalence among adolescents–
the German DMKG headache study. Cephalalgia 27(4):347–354
85. Heinrich M, Morris L, Kroner-Herwig B (2009) Self-report of
headache in children and adolescents in Germany: possibilities
and confines of questionnaire data for headache classification.
Cephalalgia 29(8):864–872
86. Mavromichalis I, Anagnostopoulos D, Metaxas N, Papanastas-
siou E (1999) Prevalence of migraine in schoolchildren and some
clinical comparisons between migraine with and without aura.
Headache 39(10):728–736
87. Zencir M, Ergin H, Sahiner T, Kilic I, Alkis E, Ozdel L et al
(2004) Epidemiology and symptomatology of migraine among
school children: Denizli urban area in Turkey. Headache
44(8):780–785
88. Akyol A, Kiylioglu N, Aydin I, Erturk A, Kaya E, Telli E et al
(2007) Epidemiology and clinical characteristics of migraine
among school children in the Menderes region. Cephalalgia
27(7):781–787
89. Koseoglu E, Nacar M, Talaslioglu A, Cetinkaya F (2003) Epi-
demiological and clinical characteristics of migraine and tension
298 J Headache Pain (2010) 11:289–299
123
type headache in 1146 females in Kayseri, Turkey. Cephalalgia
23(5):381–388
90. Anttila P, Metsahonkala L, Aromaa M, Sourander A, Salminen J,
Helenius H et al (2002) Determinants of tension-type headache in
children. Cephalalgia 22(5):401–408
91. Kaynak Key FN, Donmez S, Tuzun U (2004) Epidemiological
and clinical characteristics with psychosocial aspects of tension-
type headache in Turkish college students. Cephalalgia 24(8):
669–674
J Headache Pain (2010) 11:289–299 299
123
... Migraine is a type of primary headache that causes disability, reduces quality of life, and affects more than 1 billion people worldwide each year. The worldwide prevalence of migraine is around 11.6% (Stovner and Andree, 2010;Vetvik and MacGregor, 2017;Woldeamanuel and Cowan, 2017), with the majority of patients being under 50 years of age, and it affects more females than males (Stovner and Andree, 2010). Globally, migraines are the second-most frequent cause of disability, responsible for 16.3% of neurological symptoms and a significant impact on daily living activities (Amiri et al., 2022). ...
... Migraine is a type of primary headache that causes disability, reduces quality of life, and affects more than 1 billion people worldwide each year. The worldwide prevalence of migraine is around 11.6% (Stovner and Andree, 2010;Vetvik and MacGregor, 2017;Woldeamanuel and Cowan, 2017), with the majority of patients being under 50 years of age, and it affects more females than males (Stovner and Andree, 2010). Globally, migraines are the second-most frequent cause of disability, responsible for 16.3% of neurological symptoms and a significant impact on daily living activities (Amiri et al., 2022). ...
Article
Full-text available
Background: Migraine is a type of primary headache that is accompanied by symptoms such as nausea, vomiting, or sensitivity to light and sound. Objective: The aim of this study was to conduct a systematic review on the effectiveness of non-invasive neuromodulation, auricular transcutaneous vagus nerve stimulation (at-VNS), and electro-ear acupuncture of the vagus nerve in patients with migraine headaches. Methods: Six databases were searched from inception to 15 June 2022 for clinical trials, in which at least one group received any form of non-invasive neuromodulation of the vagus nerve for managing migraine with outcomes collected on pain intensity and related disability. Data, including participants, interventions, blinding strategy, outcomes, and results, were extracted by two reviewers. The methodological quality was assessed with the PEDro scale, ROB, and Oxford scale. Results: The search identified 1,117 publications with nine trials eligible for inclusion in the review. The methodological quality scores ranged from 6 to 8 (mean: 7.3, SD: 0.8) points. Low-quality evidence suggests some positive clinical effects for the treatment of chronic migraine with 1 Hz with at-VNS and ear-electro-acupuncture compared with the control group at post-treatment. Some of the studies provided evidence of the relationship between chronic migraine and a possible positive effect as a treatment with at-VNS and the neurophysiological effects using fMRI. Six of the studies provided evidence using fMRI of the relationship between chronic migraine and a possible positive effect as a treatment with at-VNS and the neurophysiological effects. Regarding all included studies, the level of evidence with the Oxford scale was level 1 (11.17%), six studies were graded as level 2 (66.66%), and two studies were graded as level 3 (22.2%). With the PEDro score, five studies got a low methodological score < 5 and only four got a score superior to 5, being highly methodological quality studies. For ROB, most of the studies were high risk and only a few of them received a low risk of bias. The pain intensity, migraine attacks, frequency, and duration were measured by three studies with positive results at post-treatment. And only 7% reported adverse events using at-VNS. All studies reported results at a post-treatment period in their respective main outcomes. And all studies with fMRI provided strong evidence of the relationship between the Locus Coeruleus, Frontal Cortex, and other superior brain areas with the auricular branch of the Vagus nerve with at-VNS. Conclusion: Some positive effects regarding the effect of non-invasive neuromodulation, auricular transcutaneous vagus nerve stimulation (at-VNS), and electro-ear acupuncture of the vagus nerve on migraine is reported in the current literature, but there are not enough data to obtain strong conclusions. Systematic review registration: This systematic review was registered in the PROSPERO database (registration number: CRD42021265126).
... Migraine, as a prevalent neurological disorder, remains a substantial public health concern due to its signi cant impact on individuals' quality of life and the economic burden on society (Stovner & Andree, 2010). Over the past decades, research endeavors have focused on unraveling the complex etiology of migraines, investigating the combined genetic and environmental factors that contribute to their onset and severity (Goadsby et al., 2017). ...
Preprint
Full-text available
Background Migraine, a prevalent neurological disorder, has attracted considerable attention due to its complex etiology and potential links with traits related to obesity. This study utilizes a robust two-sample Mendelian randomization (MR) framework to explore potential genetic connections between obesity, arm fat percentage (AFP, left), leg fat percentage (LFP, right), and migraine risk. Methods This study conducted a rigorous two-sample Mendelian randomization (MR) analysis using comprehensive summary-level data from genome-wide association studies (GWAS) involving obesity, AFP (left), LFP (right), and migraine. Genetic instruments were carefully chosen based on firmly established connections with the corresponding traits. The MR analysis employed various methods, including inverse variance weighted (IVW), weighted median, and MR-Egger, to evaluate causal relationships and potential pleiotropy. Results The findings offer strong evidence indicating a possible causal link between obesity and a decreased migraine risk (IVW: odds ratio [OR] = 0.91, 95% confidence interval [CI] = 0.85–0.97). Moreover, the MR analysis indicates a comparable potential causal connection between arm fat percentage (left) and a reduced risk of migraine (IVW: OR = 0.85, 95% CI = 0.75–0.98). However, no substantial causal link was found between leg fat percentage (right) and migraine risk in this study (IVW: OR = 0.99, 95% CI = 0.85–1.16). Conclusion This two-sample Mendelian randomization investigation illuminates the complex interplay between obesity-related traits and migraine risk. The findings imply a potential protective effect of obesity and arm fat percentage (left) against migraine risk, suggesting a novel approach for investigating preventive strategies. In contrast, there was no substantial causal connection observed between leg fat percentage (right) and migraine risk. These findings emphasize the significance of additional research to clarify the underlying mechanisms and clinical implications of these associations.
... The prevalence of migraines during a year varies between 10% and 15%. (12)(13)(14)(15)(16) Prior to puberty, 3-7% (15-17) of people experience migraines within a year. Nearly similar amounts of effect are felt by both genders. ...
... In present study population tension-type of headache was found to be the commonest type of headache with a prevalence of 62.90% followed by migraine headache (33.87%) and least were cluster headache (3.23%). Previous studies which had found the results similar to our study are: Stovner et al. 8 has found that tensiontype headache were more (46%) common than migraine (11%) and least was cluster headache (0.2%-0.3%); Kandil et al. 9 TTH (64%) was found to be high prevalence followed by migraine (31%) and least were cluster type of headache (4%). ...
Article
Full-text available
Background: Headache is a common neurological disorder and most disabling conditions in the worldwide. Psychiatric disorders can occur with at least two to three-fold greater frequencies among the patients presenting with headache than among general population. The presence of psychiatric co-morbidity further complicates headache management and portends a poorer prognosis. Therefore, the present study of psychiatric co-morbidity in patients presenting with primary headache and to know the nature and extent of psychiatric co-morbidity associated with headache among the patients was undertaken. Methods: Present sample consists of 62 patients who presented with the complaints of headache to the department of Psychiatry and Neuropsychiatry from August 2016 to June 2018 was included in the study. MINI 7.0.0 was applied to elicit the presence of any Psychiatric disorder. Results: In this study 65% of the patients presenting with headache had co-morbid psychiatric disorders. Out of 65% of the psychiatric illnesses; 43.55% had MDD, 14.52% had GAD, 3.23% had Panic disorder and 3.23%had Social phobia among the patients presenting with headache. Conclusions: Patients presenting with headache have high levels of co-morbid psychiatric disorders. In view of the present findings, the management of patients presenting with headache should include the detail assessment of coexisting psychopathology and treatment of both coexisting conditions.
... Migraine is a debilitating neurological disease with an estimated overall prevalence of 15% in Europe [1]. According to Kantar's 2017 National Health and Wellness Survey, 21% of adult respondents at least 18 years of age in the EU5 (France, Germany, Italy, Spain and the United Kingdom) reported experiencing migraine, with only 10% self-reporting a physician's diagnosis of migraine [2]. ...
Article
Full-text available
Background Insights into the burden, needs and treatment of migraine from internet-based surveys in diverse real-world migraine populations are needed, especially at a time when novel preventive migraine medications are becoming part of the therapeutic armamentarium. The objectives of this analysis are to describe traditional preventive (orals and onabotulinum toxin A) treatment patterns in the OVERCOME (EU) study migraine cohort, as well as treatment patterns and patient satisfaction with current treatment in a subgroup of respondents eligible for migraine preventive medication. Methods The cross-sectional non-interventional OVERCOME (EU) study was conducted (October 2020–February 2021) via an online survey among adults (aged ≥ 18 years) resident in Germany or Spain. Participants, registered in existing online panels, who were willing to provide consent were considered. The migraine cohort included participants reporting headache/migraine in the past year, identified based on a validated migraine diagnostic questionnaire and/or self-reported physician diagnosis. A subgroup of survey respondents defined as eligible for migraine preventive medication at the point in time the cross-sectional survey was taken was also analysed. Variables assessed included sociodemographic and migraine-related clinical characteristics, preventive (traditional and calcitonin gene-related peptide monoclonal antibodies) treatment patterns and patient satisfaction with current treatment. Results are descriptive only. Results Of the 20,756 participants in the migraine cohort, 78.5% sought professional medical care, 50.8% received a migraine diagnosis and only 17.7% had ever used preventive medication. Half (53.3%) of participants currently using preventives took their most recent medication for six months or less. Most patients (73.9%) classified as eligible for preventive medication (based on headache frequency and/or at least moderate disability due to migraine) reported not using traditional preventives and many of those who did (66.8%) were not satisfied with their current standard of care. Conclusions Our findings highlight the low proportion of people diagnosed with migraine despite a higher rate of consultation and suggest the need for better access to treatment for people with migraine and new preventive therapies with improved efficacy and safety profiles to improve adherence and patient satisfaction.
... A total of 97.5% of patients in the RWD are female, which is higher than prevalence estimates would suggest [40]. This may be driven by the collection of RWD through social media networks since women are more engaged in using the Internet for health-related information searching [41]. ...
Article
Full-text available
Background Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are approved in Europe as preventive treatment of migraine in patients with at least four monthly migraine days. Migraine gives rise to direct healthcare expenditures, but most of the economic burden of migraine is socioeconomic. Evidence on the socioeconomic implications of CGRP-mAbs is, however, limited. There is an increasing interest in supplementing evidence from randomised controlled trials (RCTs) with real-world evidence (RWE) to aid clinical decision making and inform decision making for migraine management. The objective of this study was to generate RWE on the health economic and socioeconomic implications of administering CGRP-mAbs to patients with chronic migraine (CM) and episodic migraine (high-frequency episodic migraine (HFEM), and low-frequency episodic migraine (LFEM)). Methods Real-world data (RWD) on Danish patients with CM, HFEM, and LFEM were collected via two Danish patient organisations and two informal patient networks and used in a tailored economic model. Treatment effects of CGRP-mAbs on health economic and socioeconomic outcomes were estimated using a sub-sample of patients with CM who receive CGRP-mAb treatment. Results A total of 362 patients (CM: 199 [55.0%], HFEM: 80 [22.1%], LFEM: 83 [22.9%]) were included in the health economic model (mean age 44.1 ± 11.5, 97.5% female, 16.3% received treatment with CGRP-mAbs), and 303 patients were included in the socioeconomic model (15.2% received treatment with CGRP-mAbs). Health economic savings from initiating CGRP-mAb treatment totalled €1,179 per patient with CM per year on average (HFEM: €264, LFEM: €175). Socioeconomic gains from initiating CGRP-mAb treatment totalled an average gross domestic product (GDP) gain of €13,329 per patient with CM per year (HFEM: €10,449, LFEM: €9,947). Conclusion Our results indicate that CGRP-mAbs have the potential to reduce both health economic expenditures and the socioeconomic burden of migraine. Health economic savings are used as a basis for health technology assessments (HTAs) of the cost-effectiveness of new treatments, which implies that important socioeconomic gains may not be given enough importance in decision making for migraine management.
Chapter
Intravenously introduced Calcitonin gene-related peptide (αCGRP) induces CGRP- induced headache (CGRP-IH) as well as cerebral and systemic hemodynamic changes detectable with transcranial Doppler sonography (TCD). Therefore, the elevation of CGRP in systemic blood can evoke a headache in predisposed subjects, especially in migraineurs. Thus, an increase in CGRP during a migraine episode might be a source of nociceptive sensation. This can induce prediction error for pain and an update of the internal homeostatic model, including headache. Furthermore, this could also turn a subject into no fit to purpose mode, leading to a disability during a migraine episode. The CGRP provocation might be used for discrimination of CGRP sensitive from insensitive migraines using TCD and to predict the CGRP antagonism effect in migraine treatment.KeywordsMigraineCalcitonine gene-related peptide (CGRP)Predictive codingGenerative modelBayesian brain
Article
Full-text available
SYNOPSIS The present study dealt with the prevalence of headache generally and migraine in particular among school children. The sample consisted of a total of 3,784 school children, accounting for 94.5% of all grade school pupils aged 13 in two Finnish cities, Tampere and Turku. The data were obtained by use of a questionnaire, filled in by the pupils according to instructions under the supervision of the class's homeroom teacher during class. Headache had occurred during 1980 in 82% of the pupils. In about one-half (53%) of the pupils it had occurred less than once a month. It occurred monthly in 9% and weekly in 8%. Frequent headache was more common in girls than in boys and was also more commonly paroxysmal in character. Boys had had headaches more often before 1980 than during 1980, whereas in girls headaches had become more common in 1980 than before. Migraine was found to occur for 11.3% of the pupils. It was more common in girls (14.5%) than in boys (8.1%). Classic migraine, in particular, occurred more often in girls. Migraine had ceased to occur prior to 1980 in 24% of cases. In particular those attacks which involved a family history of migraine, visual aura or nausea and/or vomiting had ceased to occur. Migraine too had more commonly ceased to occur in boys (23.3%) than in girls (15.1%). Comparison with previous research showed that the occurrence of migraine had more than doubled during 25 years.
Article
Full-text available
Dissertação de Doutoramento em Ciências Médicas, área de especialização em Medicina Interna, apresentada ao Instituto de Ciências Biomédicas de Abel Salazar da Universidade do Porto
Article
Background and Objectives.—Although chronic daily headache, mainly transformed migraine, is an important reason for consultation in headache clinics, its actual prevalence is unknown. This study analyzes the prevalence of the different types of chronic daily headache in an unselected population. Methods.—A questionnaire exploring headache frequency was distributed to 2252 unselected subjects. Those having headache 10 or more days per month were given a headache diary and were seen by a neurologist who classified their headaches. The varieties of chronic daily headache were classified according to the second revision of IHS criteria proposed by Silberstein et al published in Neurology 1996;47:871. Results.—The questionnaire was returned by 1883 subjects (83.5%). One hundred thirty-five admitted to headache 10 or more days per month. Chronic daily headache criteria were fulfilled by 89 individuals (4.7%). Eighty were women. Forty-two (47.2% of subjects with chronic daily headache and 2.2% of all subjects) had chronic tension-type headache. Analgesic overuse was found in 8 (17%). Transformed migraine was diagnosed in 45 (50.6% of subjects with chronic daily headache and 2.4% of all subjects). Fourteen (31.1%) individuals with this form of chronic daily headache overused ergots or analgesics. The remaining 2 cases in this series met the criteria of new daily persistent headache. No one was diagnosed as having hemicrania continua. Conclusions.—Almost 5% of the general population (9% of women) suffers from chronic daily headache, the proportion of chronic tension-type headache and transformed migraine being quite similar. Less than one third overuse analgesics. The prevalence of chronic daily headache subtypes shown here differs from data obtained from headache clinics, emphasizing that caution is needed in extrapolating data from specialized units to the general population.
Article
A questionnaire study on headaches, using a door-to-door survey, was carried out in a representative sample of the general Greek population, including 1737 men and 1764 women, from 15 to 75 years of age. The parameters evaluated included age, sex, education, socioeconomic status, region of domicile, frequency of headache, use of medication, medical consultation, and family history. Latitude and climatologic factors such as humidity, temperature, and atmospheric pressure were also investigated. Headaches were not classified because the interviewers were not specialists. Nineteen percent of men and 40% of women (mean 29%) suffered from headaches in the prior year. Headaches were more frequent in lower social classes, in people with less education, and in those between 45 and 64 years of age. Nineteen percent of sufferers did not take any medication and 33% used medication every time that they had a headache, while 36% sought medical consultation. Twenty-nine percent of headache sufferers had a family history of headaches. Daily headache was present in 15% of headache sufferers. Humidity and atmospheric pressure were not correlated to headache frequency. However, in the northern areas of Greece, as well as in the regions with low mean temperature, more people suffered from daily headaches. These data may explain the lower 1 -year prevalence of headaches in Greece as compared to the prevalence of headaches in other northern European countries.
Article
To estimate the 1-year prevalences of migraine and tension-type headache (TTH), and identify their principal risk factors, in the general population of the Republic of Georgia. In a community-based door-to-door survey, 4 medical residents interviewed all biologically unrelated adult members (>/=16 years) of 500 adjacent households in Tbilisi, the capital city, and 300 in rural Kakheti in eastern Georgia, using a previously validated questionnaire based on International Headache Society diagnostic criteria. The target population included 1,145 respondents, 690 (60%) women, mean age 45.4 +/- 12.0 years. The 1-year prevalences were as follows: migraine 6.5% (95% confidence interval 5.0-7.9), probable migraine 9.2% (7.5-10.8), all migraine 15.6% (13.5%-17.7%), TTH 10.0% (8.2-11.7), probable TTH 27.3% (24.8-29.9), all TTH 37.3% (34.5%-40.1%). Female gender and low socioeconomic status were risk factors for migraine but not for TTH. Headache on >/=15 days/month was reported by 87 respondents, a prevalence of 7.6% (6.1-9.1). Female gender, low socioeconomic status, and frequent use (>/=10 days/month) of acute headache drugs were risk factors. The likely prevalence of medication overuse headache was 0.9% (0.3-1.4), of chronic migraine 1.4% (0.7-2.1), and of chronic TTH 3.3% (2.3-4.4), but caution is needed in interpreting these estimates. While the prevalences of migraine and tension-type headache are comparable with those in Europe and the United States, a remarkably high percentage of the population of Georgia have headache on >/=15 days/month. This study demonstrates the importance of socioeconomic factors in a developing country and unmasks the unmet needs of people with headache disorders.
Article
We present a study of the general-population prevalence of cluster headache in the Republic of Georgia and discuss the advantages and challenges of different methodological approaches. In a community-based survey, specially trained medical residents visited 500 adjacent households in the capital city, Tbilisi, and 300 households in the eastern rural area of Kakheti. They interviewed all (n = 1145) biologically unrelated adult occupants using a previously validated questionnaire. The household responses rates were 92% in Tbilisi and 100% in Kakheti. The survey identified 32 persons with possible cluster headache, who were then personally interviewed by one of two headache-experienced neurologists. Cluster headache was confirmed in one subject. The prevalence of cluster headache was therefore estimated to be 87/100,000 (95% confidence interval < 258/100,000). We used a conservative approach, which has an obvious advantage of high-quality data collection, but is very demanding of manpower and time.